文献速递生殖医学

黄体期阴道孕酮栓剂与凝胶在体外受精后支持治疗中的疗效、安全性与耐受性:一项随机对照试验

Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trial.
PubMed 文献 · Hum Reprod · 2020-01-01

这项多中心、开放、随机、非劣效性3期试验比较了黄体期支持中孕酮阴道栓剂400mg每日两次与孕酮阴道凝胶90mg每日一次在体外受精后的临床妊娠率。主要终点为第38天临床妊娠率,结果显示栓剂非劣效于凝胶,两组生化妊娠率、植入率及安全性相似,药物相关不良事件发生率分别为15.1%和14.4%。

要点

  • 孕酮栓剂400mg每日两次在临床妊娠率上非劣效于孕酮凝胶90mg每日一次。
  • 两组生化妊娠率、临床植入率及安全性和耐受性相当。
  • 研究支持孕酮栓剂作为体外受精后黄体期支持的有效、安全且可耐受的选择。

核心结论

  • 孕酮阴道栓剂400mg每日两次在黄体期支持38天后的临床妊娠率上非劣效于孕酮阴道凝胶90mg每日一次。

研究设计与样本

  • 多中心、多国、开放、随机、两组平行、非劣效性3期临床试验。
  • 在5个欧洲国家的17个中心进行,共随机769名女性(栓剂组385例,凝胶组384例)。
  • 纳入18至40岁有IVF/ICSI及胚胎移植临床指征的女性。

主要发现

  • 全分析集(FAS)中,第38天临床妊娠率栓剂组为38.3%(369例),凝胶组为39.9%(368例)。
  • 符合方案集(PP)中,第38天临床妊娠率栓剂组为38.1%(357例),凝胶组为40.4%(356例)。
  • FAS中两组妊娠率差异的97.5%CI下限为-8.6%,PP中为-9.5%。
  • 预设非劣效界值-9%在FAS中满足,PP中略低于界值;但预设 logistic 回归模型显示两组95%CI下限均高于0.7,满足非劣效。
  • 药物相关不良事件发生率栓剂组为15.1%,凝胶组为14.4%。

关键数值与推荐

  • 主要终点为第38天经阴道超声测胎心搏动评估的临床妊娠率。
  • 非劣效界值原为-9%,后经相关机构接受放宽至-10%,FAS和PP均显示非劣效。
  • 生化妊娠率通过血清β-hCG ≥25 IU/L评估,两组相当。

临床怎么用

  • 对于接受IVF的女性,黄体期支持可选用孕酮阴道栓剂400mg每日两次,其疗效和安全性与孕酮阴道凝胶90mg每日一次相当。
  • 临床选择时应考虑患者偏好、耐受性和成本等因素。

局限性

  • 临床妊娠率是活产率的替代终点。
  • 研究为开放设计,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are progesterone vaginal pessaries 400 mg twice a day (bid) non-inferior to progesterone vaginal gel (90 mg) once a day (od) in the primary endpoint of clinical pregnancy rate after 38 days of luteal phase support in women undergoing in vitro fertilisation (IVF)? SUMMARY ANSWER: Non-inferiority of progesterone vaginal pessaries 400 mg bid to progesterone 8% vaginal gel (90 mg od) was shown for clinical pregnancy rate after 38 days of luteal phase support. WHAT IS KNOWN ALREADY: To maximise successful embryo transfer after IVF, additionally administered progesterone is used for proper endometrium transformation in the luteal phase. Vaginally administered progesterone results in adequate secretory transformation of the endometrium. STUDY DESIGN, SIZE, DURATION: This multicentre, multinational, open, randomised, two-parallel group, non-inferiority Phase 3 clinical trial was carried out at 17 study sites in five European countries (Belgium, Bulgaria, Czech Republic, Hungary and Serbia) between October 2013 and August 2014. An interactive web response system (IWRS) was implemented for treatment allocation at the sites. Power analysis, based on the assumptions of a non-inferiority margin of -9%, a significance level of α 2.5% (one-sided), power 90%, at a reference pregnancy rate for the progesterone vaginal gel group of 30%, as well as applying a dropout rate of 10%, yielded a total number of 766 patients to be randomised. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women aged between 18 and 40 years with a clinical indication for IVF/intracytoplasmic sperm injection (ICSI) and embryo transfer were eligible to participate. The clinical pregnancy rate was assessed by fetal heart movement measured by transvaginal ultrasound at day 38 (D38) (primary endpoint) and D70. Also assessed were biochemical pregnancy rate (assessed by serum β-hCG ≥25 IU/L), clinical implantation rates at D38, patient evaluation of vaginal bleeding and discharge (assessed by diary) and adverse event (AE) incidence, severity and relationship to study medication. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 769 female patients were randomised to progesterone 400 mg vaginal pessaries bid (n = 385, 50.1%) or progesterone 90 mg vaginal gel od (n = 384, 49.9%). Patients receiving progesterone vaginal pessaries and progesterone vaginal gel were comparable in demographics, baseline characteristics and number of retrieved oocytes. In the full analysis set (FAS; n = 369 progesterone vaginal pessaries and n = 368 progesterone vaginal gel), clinical pregnancy rates on D38 were 38.3% for progesterone vaginal pessaries and 39.9% for progesterone vaginal gel. In the per protocol analysis set (PP; n = 357 progesterone vaginal pessaries and n = 356 progesterone vaginal gel), clinical pregnancy rates on D38 were 38.1% for progesterone vaginal pessaries and 40.4% for progesterone vaginal gel. For the differences in pregnancy rates between the progesterone vaginal pessaries group and the progesterone vaginal gel, the lower limit of the 97.5% CI was -8.6 and -9.5% for the FAS and PP datasets, respectively. The original prespecified non-inferiority margin of -9% was thus met in the FAS dataset but was marginally below this in the PP dataset. However, the pregnancy rate of the comparator was higher than the anticipated rate of 30%, and a predetermined logistic regression model including treatment group, country and age group effects without interaction terms showed non-inferiority of progesterone vaginal pessaries to progesterone vaginal gel for both the FAS and PP populations, in that the lower limits of the 95% CIs were above 0.7 for both analyses. As a result of this, the relevant authorities accepted to widen the acceptable non-inferiority margin to -10%, and as such both the FAS and PP populations succeeded in showing non-inferiority. Biochemical pregnancy and clinical implantation rates were comparable for both treatments. Both treatment groups showed similar high compliance throughout the study, and the safety profiles were also comparable between the groups. Drug-related AEs occurred with frequencies of 15.1% with progesterone vaginal pessaries and 14.4% with progesterone vaginal gel. LIMITATIONS, REASONS FOR CAUTION: Clinical pregnancy rate is a surrogate for the outcome of live birth rate. WIDER IMPLICATIONS OF THE FINDINGS: Progesterone 400 mg pessaries bid for luteal phase support is an effective, safe and tolerable treatment option for women undergoing IVF during ART. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by Actavis Group PTC ehf., Iceland, part of Teva Pharmaceuticals, and by L.D. Collins & Co. Ltd. Gedeon Richter plc has recently entered into a license and distribution agreement to commercialise the vaginal pessaries in the European Union (except Ireland/UK). The progesterone vaginal pessaries studied are now marketed as Cyclogest®, Amelgen®, Cyclovita®, Luteum and Cygest® throughout the EU, Asia and Middle East & North Africa. The competing interests are as follows. H.S.: employee of Gedeon Richter plc/PregLem S.A. C.K.: consultant to L.D. Collins & Co. Ltd and received consulting fees for work performed. T.D.H.: at the initiation and completion of this study, full professor at KU Leuven and Head of Leuven University Fertility Center at the University Hospital Gasthuisberg, Leuven, Belgium. In October 2015, T.D.H. became vice president of Global Medical Affairs Fertility at the pharmaceutical company Merck-marketing authorisation holder of the Progesterone vaginal gel (Crinone®)-and has remained a part-time professor at KU Leuven (Belgium) and adjunct professor at Yale University (New Haven, CT, USA). T.B.M.: at the initiation and completion of this study, employee of Actavis Group PTC ehf. I.K.: consultant to Actavis, later TEVA and received consulting fees for work performed. S.H.: at the initiation and completion of this study, employee of Actavis Group PTC ehf. TRIAL REGISTRATION NUMBER: EudraCT number 2013-001105-81. TRIAL REGISTRATION DATE: 2 July 2013. DATE OF FIRST PATIENT’S ENROLMENT: 9 October 2013.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Saunders H, Khan C, D'Hooghe T, et al. Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trial. Hum Reprod. 2020. PMID: 32074281. doi:10.1093/humrep/dez261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。